Late-Breaking Data at EULAR Shows Investigational Drug Nipocalimab Significantly Reduces Disease Activity in Lupus
Lupus Therapeutics, clinical affiliate of the Lupus Research Alliance, is encouraged by positive late-breaking Phase 2 data with nipocalimab, an investigational drug in development by Johnson...